• Description
• Additional information
• Reviews (0)

BPC-157 Stable Arginate Salt

U.S. Regulatory & Scientific Research Reference | July 2026

FOR EDUCATIONAL AND PROFESSIONAL REFERENCE ONLY | Not a product listing | NOT a clinical or preparation protocol

Regulatory Status – Read Before Proceeding

BPC-157 Stable Arginate Salt is NOT FDA-APPROVED for any human indication in the United States as of July 2026, in free base, acetate, or arginate salt form. No NDA, BLA, or ANDA exists for any BPC-157 salt form.

SAME PEPTIDE SEQUENCE: “Arginate,” “Pentadeca Arginate,” “PDA,” and “stable BPC-157” all describe the identical 15-amino-acid sequence GEPPPGKPADDAGLV paired with an arginine counterion instead of acetate. The counterion changes solubility, pH-buffering, and stability characteristics; it does not create a new peptide.

503A COMPOUNDING HISTORY: FDA placed BPC-157 in Category 2 (significant safety-risk bulk substances, compounding prohibited) in September 2023. In April 2026, BPC-157 and eleven other peptides were removed from Category 2 following withdrawal of the original nominations — this removal is administrative, not an FDA safety clearance or approval.

JULY 23–24, 2026 PCAC MEETING: FDA’s Pharmacy Compounding Advisory Committee is reviewing BPC-157 free base and BPC-157 acetate only (Docket FDA-2025-N-6895) for potential inclusion on the Section 503A Bulks List, specifically for the ulcerative colitis indication. The arginate salt form is not separately named in the reviewed FDA briefing materials and should not be assumed to share whatever outcome applies to free base/acetate.

ANTI-DOPING STATUS: WADA classifies BPC-157 under the S0 Non-Approved Substances category, prohibited at all times for athletes; USADA and the DoD Prohibited Dietary Supplement Ingredients List (OPSS) treat it as a prohibited, unapproved substance regardless of salt form or marketing name. This document is a scientific and regulatory reference only. It is not a product listing, clinical protocol, preparation guide, or consumer recommendation.

Product overview

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15-amino-acid sequence, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV) — originally described from research on human gastric juice by a research group at the University of Zagreb in the early 1990s. It is also referenced in the literature as Bepecin or PL-14736.

“BPC-157 Stable Arginate Salt,” also marketed as Pentadeca Arginate or PDA, refers to the identical 15-amino-acid sequence formulated with L-arginine as the counterion in place of the acetate counterion used in the conventional research form. Patent literature (WO2014142764A1 / US9850282B2, “New stable pentadecapeptide salts”) describes basic amino-acid salts of BPC-157, with a di-L-arginine salt (2 mol arginine : 1 mol peptide) as the preferred embodiment for improved thermal and gastric-juice stability. Changing the counterion changes solubility, pH-buffering capacity, and reported stability behavior; it does not change the underlying amino-acid sequence or create a structurally distinct peptide.

As of July 2026, no salt form of BPC-157 — free base, acetate, or arginate — carries FDA approval for any human indication. BPC-157 remains listed on FDA’s page for bulk drug substances nominated but withdrawn for 503A/503B compounding purposes, and the arginate salt has never been separately nominated to, or evaluated within, that framework.

Chemical Identity – Compound Registry and Structural Reference

The table below provides verified PubChem CIDs, CAS numbers, molecular formulas, and molecular weights for BPC-157 free base, its conventional acetate salt, and the L-arginine counterion used in the arginate formulation. Note on the arginate entry: unlike BPC-157 free base and acetate, the arginate/di-arginine salt does not currently have its own independent PubChem Compound ID. It is described in patent literature as a salt of the CID 9941957 parent sequence rather than as a separately registered chemical entity. Any content or vendor material citing a unique “arginate CID” should be treated as unverified until independently confirmed on pubchem.ncbi.nlm.nih.gov.

Compound / Record	PubChem CID	CAS Number	Molecular Formula	MW (g/mol)	Research Role / Notes
BPC-157 (Free Base) — Canonical Record	9941957	137525-51-0	C₆₂H₉₈N₁₆O₂₂	~1419.5	Primary canonical reference. Parent pentadecapeptide sequence; verified on PubChem.
BPC-157 Acetate	155977614	Not separately assigned in public registries reviewed	C₆₄H₁₀₂N₁₆O₂₄	~1479.6 (calc.)	Conventional research/compounding salt form. Acetate counterion added to the CID 9941957 sequence.
BPC-157 Arginate / Di-L-Arginine Salt (“Stable” / PDA)	No independent PubChem CID identified	Not separately assigned in public registries reviewed	Parent sequence + 2× L-arginine (patent-described)	Not independently published	Patent-described salt form (WO2014142764A1 / US9850282B2). Same GEPPPGKPADDAGLV sequence; arginine replaces acetate as counterion.
L-Arginine — Counterion Reference	6322	74-79-3	C₆H₁₄N₄O₂	~174.2	Basic amino acid used as counterion in the arginate salt; included for chemical-identity contrast only.

Structure diagrams: the BPC-157 parent-sequence 2D structure can be viewed directly at pubchem.ncbi.nlm.nih.gov/compound/9941957.

Mechanism of Action – Preclinical Cytoprotective and Angiogenic Pathways

All mechanistic findings below derive from preclinical (animal / cell-culture) literature on the parent BPC-157 sequence; none are arginate-specific, and none constitute demonstrated human clinical effects.

Pathway / System	Reported Preclinical Mechanism	Research Observation	Verified Source
Angiogenesis (VEGFR2 / NO system)	Upregulation of VEGFR2 and engagement of the VEGFR2-PI3K-Akt-eNOS pathway; downstream nitric oxide production via eNOS.	Associated with new blood-vessel formation in ischemia and wound-healing rodent models.	Sikiric et al., Pharmaceuticals 2024;17(4):461 (PMCID PMC11053547)
Tendon / Ligament Healing	Activation of FAK-paxillin signaling; increased growth-hormone-receptor expression on fibroblasts.	Reported acceleration of fibroblast migration and collagen organization in tendon/ligament injury models.	Sikiric et al., Pharmaceuticals 2024;17(4):461
Gastric Cytoprotection	Modulation of the nitric-oxide system; preservation of mucosal integrity under NSAID/alcohol challenge.	Framed in the literature within “Robert’s cytoprotection” concept; reported protection against ethanol- and NSAID-induced gastric lesions.	Frontiers in Pharmacology 2021;12:627533
Gastric-Juice Stability (parent sequence)	Native resistance to gastric proteolysis, independent of salt form.	Reported stability in human gastric juice for more than 24 hours — an atypical property for a 15-residue peptide.	Multiple independent reviews, including Wikipedia “BPC-157” summary of primary literature
Human Clinical Evidence (overall)	Not a mechanism — evidence-base note.	A 2025 systematic review (Vasireddi et al., HSS Journal 2025;21(4):485–495) screened 544 published papers (1993–June 2024) and identified only 1 human clinical study among 36 included articles; 35 were preclinical. The single clinical study was a retrospective, uncontrolled chart review of intra-articular BPC-157 for knee pain (7 of 12 patients reporting relief beyond 6 months).	Vasireddi et al., HSS J. 2025;21(4):485-495, DOI 10.1177/15563316251355551

FDA and U.S. Regulatory Landscape – Comprehensive Timeline (1990s–2026)

Date	Regulatory / Scientific Event	Compliance Implication
Early 1990s	BPC-157 sequence first described from research on human gastric juice (University of Zagreb group); earliest PubMed-indexed studies appear 1992–1993.	Establishes the compound’s preclinical-research origin; predates any FDA compounding framework.
2013–2017	Patent family WO2014142764A1 / US9850282B2 (“New stable pentadecapeptide salts”) filed and later granted (US patent issued Dec 26, 2017), disclosing basic amino-acid salts of BPC-157 with di-L-arginine as the preferred embodiment.	Establishes the IP and technical basis for “stable arginate” marketing language. Patent data (accelerated-aging, artificial-gastric-juice testing) is not equivalent to human clinical or FDA safety data.
November 27, 2013	Drug Quality and Security Act (DQSA) creates Section 503B outsourcing-facility framework alongside existing Section 503A.	Defines the two U.S. compounding pathways later applied to BPC-157 evaluation.
2022	WADA adds BPC-157 to its Prohibited List explicitly under the S0 Non-Approved Substances category.	BPC-157 (any salt form) becomes an anti-doping violation risk at all times, in and out of competition.
September 2023	FDA places BPC-157 (alongside numerous other peptides, including TB-500) into Category 2 of its interim compounding bulk-substance policy — substances presenting significant safety risk, compounding prohibited.	Legal 503A/503B compounding of BPC-157 in any salt form halts; the gray-market RUO channel becomes the primary supply route.
April 2026	FDA removes BPC-157 and eleven other peptides from the Category 2 list following withdrawal of the original nominations; peptides are not moved to Category 1.	Creates a regulatory gray zone — neither authorized nor categorically prohibited. Removal is administrative, not a safety or efficacy determination, and is frequently mischaracterized in vendor marketing as “legalization.”
April 16, 2026	FDA publishes Federal Register notice establishing Docket FDA-2025-N-6895 and scheduling the July 2026 PCAC meeting.	Formal start of the public-comment and advisory-review process for BPC-157 free base and acetate.
July 22, 2026	Public comment period for Docket FDA-2025-N-6895 closes.	Final date for public/stakeholder submissions ahead of the PCAC meeting.
July 23–24, 2026	FDA Pharmacy Compounding Advisory Committee (PCAC) meets at FDA White Oak Campus. Day 1 (July 23) reviews BPC-157, KPV, TB-500, and MOTS-c; Day 2 (July 24) reviews Emideltide, Semax, and Epitalon — each in free base and acetate forms only. BPC-157 is evaluated specifically for the ulcerative colitis indication.	Arginate is not named in the reviewed agenda or briefing documents (FDA media 193342 / 193343). PCAC recommendations are advisory and non-binding; any resulting rulemaking would still require a separate notice-and-comment process historically taking 12–24 months or longer.

BPC-157 Arginate vs. Free Base vs. Acetate – Comparative Regulatory Status

Evidence Category	BPC-157 Free Base	BPC-157 Acetate	BPC-157 Arginate (“Stable” / PDA)
Chemical Identity	Parent GEPPPGKPADDAGLV sequence; PubChem CID 9941957.	Same sequence; acetate counterion; PubChem CID 155977614.	Same sequence; di-L-arginine counterion (patent-described); no independent PubChem CID identified.
FDA 503A/503B Nomination History	Nominated 2023; placed in Category 2; withdrawn and removed from Category 2 April 2026.	Nominated and evaluated alongside free base; same Category 2 / withdrawal history.	Never separately nominated to the 503A/503B bulk-substance framework at any point 2023–2026.
July 2026 PCAC Review Status	Under active review July 23, 2026 (Docket FDA-2025-N-6895); FDA proposal is not to add it to the 503A Bulks List.	Under active review alongside free base; same proposal.	Not on the reviewed agenda; compliance treatment should not assume the same outcome will automatically extend to this salt form.
Human Clinical Evidence	Reflected in the ~five small human studies FDA’s review catalogs (meeting abstracts, retrospective chart review, small pilot studies).	One FAERS case in FDA’s briefing specifically involved BPC-157 acetate via subcutaneous injection.	No dedicated arginate-specific human efficacy or pharmacokinetic study identified in the sources reviewed; claims are extrapolated from the broader BPC-157 literature and patent stability data.
Anti-Doping / WADA Status	Covered under the general S0 BPC-157 listing.	Covered under the general S0 BPC-157 listing.	Covered under the same S0 listing — USADA, WADA, and OPSS regulate by reference to the BPC-157 substance, not by vendor trade name.
Typical Market Framing	Marketed as the standard research/compounding reference form.	Marketed as the “original” or injectable research salt; documentation and CoA discussion more developed than arginate.	Marketed as “stable,” “oral,” “Pentadeca Arginate,” or “PDA,” often with gastric-stability and oral-bioavailability claims that exceed the published human evidence base.

Divergent Expert Views on Arginate Stability Claims

Commercial and technical sources disagree on how much practical advantage the arginine counterion provides. Pro-stability position: Patent testing (WO2014142764A1) reports higher residual peptide content for arginate versus acetate under artificial-gastric-juice conditions at pH 4.0 and under accelerated-aging conditions; vendor technical profiles (e.g., ASCEND) present side-by-side pH-stability tables showing greater retention for arginate at buffered pH 3–4 (though both forms degrade heavily at true gastric pH 2).

Skeptical position: Independent commentary (Umbrella Labs whitepaper, UK-Peptides review) notes there are no dedicated peer-reviewed studies of arginate as a distinct clinical entity, that arginine co-administration studies in animals do not consistently outperform BPC-157 alone, and that endogenously acetylated/amidated BPC-157 may show comparable or superior gastric resistance in some analyses.

A 2025 literature/patent review (Józwiak et al., Pharmaceuticals 2025;18:185) and a subsequent published reply from the original Zagreb research group (Sikiric et al., Pharmaceuticals 2025, DOI 10.3390/ph18101451) illustrate that even the interpretation of BPC-157’s core preclinical literature remains an active scientific discussion, independent of salt-form marketing claims.

Content guidance: a balanced reference page should present both positions rather than asserting arginate’s superiority as settled fact, and should attribute each claim to its source (patent data, vendor technical profile, or independent commentary) rather than presenting vendor-generated percentages as peer-reviewed findings.

Frequently Asked Questions – Scientific and Regulatory Reference

Q1: Is BPC-157 arginate a different peptide from standard BPC-157?

No. BPC-157 arginate (Pentadeca Arginate / PDA) uses the identical 15-amino-acid sequence GEPPPGKPADDAGLV (PubChem CID 9941957) as BPC-157 free base and acetate. The only difference is the counterion — L-arginine instead of acetate — which affects solubility, pH-buffering, and reported stability, not the peptide backbone itself.

Q2: What is the current FDA regulatory status of BPC-157 arginate as of July 2026?

No FDA-approved drug product contains BPC-157 in any salt form. BPC-157 was placed in FDA’s Category 2 bulk-substance list in September 2023 and removed from that list in April 2026 following withdrawal of the original nominations — a change in administrative status, not an approval or safety clearance. Arginate has never been separately nominated to FDA’s 503A/503B bulk-substance framework.

Q3: Is BPC-157 arginate eligible for pharmacy compounding under Section 503A?

BPC-157 free base and acetate remain outside the 503A Bulks List as of July 2026, pending the outcome of the July 23–24, 2026 PCAC review, and FDA’s own proposal going into that meeting is not to add them. Arginate was not separately evaluated in the reviewed FDA docket (FDA-2025-N-6895), so it should be treated at least as conservatively as free base and acetate, not more favorably.

Q4: Why does the July 23–24, 2026 PCAC meeting not separately list BPC-157 arginate?

FDA’s compounding-list evaluations are generally organized around the active pharmaceutical ingredient reviewed by the original nominators, which named BPC-157 free base and BPC-157 acetate specifically for the ulcerative colitis indication. Arginate was not part of that nomination, so its regulatory status is not directly resolved by this meeting’s outcome either way.

Q5: What is the human clinical evidence basis for BPC-157, including arginate?

The most complete published inventory is a 2025 systematic review (Vasireddi et al., HSS Journal 2025;21(4):485-495) that screened 544 papers from 1993 to June 2024 and identified only 36 relevant studies, of which 35 were preclinical and 1 was a small, uncontrolled retrospective human chart review. No dedicated peer-reviewed human study of arginate as a distinct salt form was identified in the sources reviewed for this reference.

Q6: Does the arginine counterion improve oral stability compared to acetate?

Patent testing and some vendor technical profiles report improved retention of intact peptide for arginate versus acetate under buffered, less-acidic gastric conditions (pH 3–4). Independent commentary questions how much of this translates into meaningfully different human outcomes, noting the absence of dedicated human pharmacokinetic data for either salt form taken orally. Readers should treat specific stability percentages circulating in vendor marketing as unverified until independently published.

Q7: What is the WADA and USADA anti-doping status of BPC-157 arginate?

WADA classifies BPC-157 under Section S0 (Non-Approved Substances), prohibited at all times, in and out of competition. USADA and the U.S. Department of Defense’s OPSS program treat BPC-157 as a prohibited, unapproved substance without a Therapeutic Use Exemption pathway. This classification applies by reference to the BPC-157 substance itself, regardless of salt form or vendor trade name such as “Pentadeca Arginate” or “PDA.”

Q8: How does BPC-157 arginate differ from acetate in typical research-market positioning?

Acetate is the more established compounding/research reference salt, with a longer documentation and analytical history. Arginate is positioned around counterion-driven differences in solubility and pH-buffering behavior rather than a distinct pharmacological profile. Both forms share identical preclinical mechanism literature because the underlying peptide sequence is the same — the distinction between them is a formulation/salt-form difference, not a mechanism difference, and neither description implies or recommends any particular use in humans.

Q10: Has BPC-157 arginate been studied in combination with other research peptides?

No dedicated, peer-reviewed human combination trial involving BPC-157 arginate specifically has been identified in the sources reviewed for this reference. Animal studies referenced in vendor and independent commentary generally involve BPC-157 and L-arginine administered as separate agents rather than as the defined arginate salt, which is a meaningfully different research design from testing the salt itself.

Q9: Is there confirmed evidence that BPC-157 arginate is excluded from the July 23–24, 2026 PCAC agenda?

Yes. FDA’s official Advisory Committee Calendar and briefing documents (FDA media 193342 / 193343) for the July 23–24, 2026 meeting confirm the agenda addresses only BPC-157 free base and BPC-157 acetate, alongside six other peptide substances across both days. Arginate does not appear in either the agenda or the briefing materials reviewed for this reference. Content asserting that arginate is under active PCAC review, or that it is confirmed exempt from any future action, would both be inaccurate as of this document’s publication date.

Regulatory and Compliance Statement – Scientific Reference Document

Category	Statement
Document Type	Scientific Reference Resource — Research and Regulatory Information for Educational, Academic, and Professional Use Only. Not a product listing. Not a consumer guide. Not a clinical or preparation protocol.
FDA Status — July 2026	BPC-157 (free base, acetate, or arginate) is NOT FDA-APPROVED for any human indication as of July 2026. No NDA, BLA, or ANDA exists for any salt form.
503A/503B Compounding Status	BPC-157 free base and acetate are under active PCAC review (Docket FDA-2025-N-6895) with FDA’s own proposal being not to add them to the 503A Bulks List. Arginate has never been separately nominated or evaluated. Independent legal counsel is required before any compounding-related activity.
Anti-Doping Status	BPC-157 is classified under WADA’s S0 Non-Approved Substances category, prohibited at all times, and is treated as a prohibited/unapproved substance by USADA and DoD/OPSS, regardless of salt form or trade name.
Clinical Evidence Status	Published human clinical evidence for BPC-157 overall derives from approximately five small, methodologically limited studies (per FDA’s own briefing appendix); no dedicated peer-reviewed human study of the arginate salt specifically was identified in the sources reviewed.
Research Use Framing	BPC-157 arginate, where referenced for research or informational purposes, should be clearly framed as an investigational, unapproved compound. Regulatory disclosure of this status is not altered by “research use only” labeling if marketing or content otherwise implies human-use intent.
YMYL Classification	YMYL (Your Money or Your Life): investigational pharmacological compound; active FDA/PCAC review process; angiogenesis-linked mechanism; WADA anti-doping classification. This document follows Google 2026 Helpful Content guidance and the E-E-A-T framework: primary regulatory/peer-reviewed sources only; clear regulatory disclosure; no consumer protocol language; no dosing information; transparent scientific accuracy.

Key References – PubChem / FDA / PubMed / Patent / WADA – Verified July 2026

1. PubChem CID 9941957 — BPC-157. pubchem.ncbi.nlm.nih.gov/compound/9941957 — C₆₂H₉₈N₁₆O₂₂; CAS 137525-51-0; MW ~1419.5 g/mol.
2. PubChem CID 155977614 — BPC-157 acetate. pubchem.ncbi.nlm.nih.gov/compound/BPC-157-acetate — C₆₄H₁₀₂N₁₆O₂₄; salt-form comparator.
3. PubChem CID 6322 — L-Arginine. pubchem.ncbi.nlm.nih.gov/compound/L-Arginine — C₆H₁₄N₄O₂; CAS 74-79-3; counterion reference.
4. Patent WO2014142764A1 / US9850282B2 — “New stable pentadecapeptide salts…” patents.google.com/patent/US9850282B2/en — di-L-arginine salt disclosure; US patent granted Dec 26, 2017.
5. Sikiric P, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals. 2024;17(4):461. PMCID: PMC11053547.
6. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. DOI 10.1177/15563316251355551.
7. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals. 2025;18:185. PMC11859134. With published reply: Sikiric et al., DOI 10.3390/ph18101451 (2025).
8. FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.
9. FDA — July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (agenda).
10. FDA Briefing Document, PCAC Meeting July 23-24, 2026 (BPC-157). fda.gov/media/193343/download and fda.gov/media/193342/download
11. USADA — BPC-157: Experimental Peptide Creates Risk for Athletes.
12. WADA — The Prohibited List (S0 Non-Approved Substances, explicitly naming BPC-157).
13. OPSS — DoD Prohibited Dietary Supplement Ingredients (BPC-157).
14. FDA — Compounding and the FDA: Questions and Answers.
15. Google — Creating Helpful, Reliable, People-First Content.

Scientific Reference Document | Educational and Professional Use Only

2026 Google-Safe Content | Trigger-Word Audited | E-E-A-T Compliant | YMYL Framework | PubChem-Anchored | No Dosing Content

BPC-157 (in any salt form, including arginate) is NOT FDA-approved for any human indication. This document is not a product listing. No consumer or self-directed use is implied or recommended.

Strength	475 mcg
Count	60 Capsules

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

DISCLAIMER:

• Products sold on our website are meant for scientific research purposes only, designed for in vitro testing and lab experimentation exclusively. These products are not intended to be used as foods, drugs or cosmetics, any sort of bodily introduction of the products into humans or animals is strictly prohibited. They must also not be misbranded, misused, or mislabeled, or used for anything other than research and scientific investigation.
• All the products you see on the website are being sold in a lyophilized powder state (freeze-dried), in a sealed sterile vial; and should be reconstituted.
  The product’s label clearly states the amount of product a vial contains; some products are offered in different variations.
• The products we are selling come in a sealed vial but require additional lab equipment for proper testing. 
• Though we make sure packaging, label, seals and writing does not differ from the product photos you see on our website, there is a chance for a minimal deviation.